{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:06:12Z","timestamp":1790773572415,"version":"4.1.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/ijem.ijem_79_18","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T03:19:12Z","timestamp":1533007152000},"page":"552","source":"Crossref","is-referenced-by-count":42,"title":["Hepatogenous diabetes: An underestimated problem of liver cirrhosis"],"prefix":"10.4103","volume":"22","author":[{"given":"Ramesh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.238127-1","first-page":"e218","volume-title":"Regulation of glucose metabolism from a liver-centric perspective","author":"Han","year":"2016","journal-title":"Exp Mol Med"},{"key":"key-10.4103\/2230-8210.238127-2","first-page":"84","volume-title":"Diabetes and nonalcoholic fatty liver disease: A pathogenic duo","author":"Williams","year":"2013","journal-title":"Endocr Rev"},{"key":"key-10.4103\/2230-8210.238127-3","first-page":"280","volume-title":"Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management","author":"Garcia-Compean","year":"2009","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-4","first-page":"1822","volume-title":"Diabetes increases the risk of acute hepatic failure","author":"El-Serag","year":"2002","journal-title":"Gasteroenterology"},{"key":"key-10.4103\/2230-8210.238127-5","first-page":"13","volume-title":"Hepatogenous diabetes.Current views of an ancient problem","author":"Garc\u00eda-Compean","year":"2009","journal-title":"Ann Hepatol"},{"key":"key-10.4103\/2230-8210.238127-6","first-page":"1051","volume-title":"Glucose tolerance and diabetes in chronic liver disease","author":"Megyesi","year":"1967","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.238127-7","first-page":"45","volume-title":"The current state of diabetes mellitus in India","author":"Kaveeshwar","year":"2014","journal-title":"AMJ"},{"key":"key-10.4103\/2230-8210.238127-8","first-page":"950","volume-title":"Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?","author":"Orsi","year":"2017","journal-title":"Liver Int"},{"key":"key-10.4103\/2230-8210.238127-9","first-page":"524","volume-title":"Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus","author":"Kim","year":"2006","journal-title":"Korean J Hepatol"},{"key":"key-10.4103\/2230-8210.238127-10","first-page":"677","volume-title":"Clinical implications of hepatogenous diabetes in liver cirrhosis","author":"Holstein","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"key-10.4103\/2230-8210.238127-11","first-page":"918","volume-title":"Significance of oral glucose tolerance test for the diagnosis of diabetes mellitus in patients with liver cirrhosis","author":"Imano","year":"1999","journal-title":"Intern Med"},{"key":"key-10.4103\/2230-8210.238127-12","first-page":"2284","volume-title":"Determination of glycated hemoglobin in patients with advanced liver disease","author":"Lahousen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-13","first-page":"70","volume-title":"Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis","author":"Nishida","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-14","first-page":"240","volume-title":"The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis.A prospective study","author":"Garc\u00eda-Compe\u00e1n","year":"2012","journal-title":"Ann Hepatol"},{"key":"key-10.4103\/2230-8210.238127-15","first-page":"1484","volume-title":"Contribution of \u03b2-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease","author":"Grancini","year":"2015","journal-title":"J Hepatol"},{"key":"key-10.4103\/2230-8210.238127-16","first-page":"3335","volume-title":"Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage","author":"Jeon","year":"2013","journal-title":"Dig Dis Sci"},{"key":"key-10.4103\/2230-8210.238127-17","first-page":"74958","volume-title":"Glucose intolerance in liver cirrhosis: Role of hepatic and non-hepatic influences","author":"M\u00fcller","year":"1994","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"key-10.4103\/2230-8210.238127-18","first-page":"4606","volume-title":"Hepatitis B and C virus infection and diabetes mellitus: A cohort study","author":"Hong","year":"2017","journal-title":"Sci Rep"},{"key":"key-10.4103\/2230-8210.238127-19","first-page":"693","volume-title":"Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis","author":"Cai","year":"2015","journal-title":"Exp Ther Med"},{"key":"key-10.4103\/2230-8210.238127-20","first-page":"870\u201375","volume-title":"Mechanisms of hyperinsulinaemia in child's disease grade B liver cirrhosis investigated in free living conditions","author":"Greco","year":"2002","journal-title":"Gut"},{"key":"key-10.4103\/2230-8210.238127-21","first-page":"144452","volume-title":"Studies on histopathology of pancreas in portal hypertension","author":"Saitoh","year":"1984","journal-title":"Nippon Shokakibyo Gakkai Zasshi"},{"key":"key-10.4103\/2230-8210.238127-22","first-page":"S262\u20138","volume-title":"Insulin resistance and hyperinsulinemia: Is hyperinsulinemia the cart or the horse?","author":"Shanik","year":"2008","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.238127-23","first-page":"141\u20139","volume-title":"Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity","author":"Petrides","year":"1998","journal-title":"Hepatology"},{"key":"key-10.4103\/2230-8210.238127-24","first-page":"16","volume-title":"Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside","author":"Gariani","year":"2013","journal-title":"Diabetes Metab"},{"key":"key-10.4103\/2230-8210.238127-25","first-page":"1096\u20131101","volume-title":"Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case- control study","author":"Lecube","year":"2006","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.238127-26","first-page":"S56\u201365","volume-title":"The interaction of metabolic factors with HCV infection: Does it matter?","author":"Bugianesi","year":"2012","journal-title":"J Hepatol"},{"key":"key-10.4103\/2230-8210.238127-27","first-page":"6315\u201322","volume-title":"Hepatitis C virus activates the mTOR\/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance","author":"Bose","year":"2012","journal-title":"J Virol"},{"key":"key-10.4103\/2230-8210.238127-28","first-page":"558\u20135","volume-title":"Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A","author":"Christen","year":"2007","journal-title":"Hepatology"},{"key":"key-10.4103\/2230-8210.238127-29","first-page":"5\u201312","volume-title":"The haemochromatotic human pancreas: A quantitative immunohistochemical and ultrastructural study","author":"Rahier","year":"1987","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.238127-30","first-page":"1696\u2013705","volume-title":"The incretin system: Glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase4 inhibitors in type 2 diabetes","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.238127-31","first-page":"242","volume-title":"Dipeptidyl peptidase IV (DDP IV) in NASH patients","author":"Balaban","year":"2007","journal-title":"Ann Hepatol"},{"key":"key-10.4103\/2230-8210.238127-32","first-page":"2298","volume-title":"Dipeptidyl peptidase-4: A key player in chronic liver disease","author":"Itou","year":"2013","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-33","first-page":"39\u201345","volume-title":"Elevation of Ne-(carboxymethyl) lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis","author":"Yagmur","year":"2006","journal-title":"Clin Biochem"},{"key":"key-10.4103\/2230-8210.238127-34","first-page":"66\u201371","volume-title":"Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation","author":"Sebekova","year":"2002","journal-title":"J Hepatol"},{"key":"key-10.4103\/2230-8210.238127-35","first-page":"453","volume-title":"Advanced glycation end products (AGE) and diabetes: Cause, effect, or both?","author":"Vlassara","year":"2014","journal-title":"Curr Diab Rep"},{"key":"key-10.4103\/2230-8210.238127-36","first-page":"98\u2013105","volume-title":"Abnormal tissue oxygenation in patients with cirrhosis and liver failure","author":"Moreau","year":"1988","journal-title":"J Hepatol"},{"key":"key-10.4103\/2230-8210.238127-37","first-page":"2171\u201383","volume-title":"Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets","author":"Cheng","year":"2010","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.238127-38","doi-asserted-by":"crossref","unstructured":"Yi P, Park J-S, Melton DA. Betatrophin: A hormone that controls pancreatic b cell proliferation. Cell 2013;153:747\u201358.","DOI":"10.1016\/j.cell.2013.04.008"},{"key":"key-10.4103\/2230-8210.238127-39","first-page":"10949","volume-title":"Higher plasma betatrophin\/ANGPTL8 level in type 2 diabetes subjects does not correlate with blood glucose or insulin resistance","author":"Abu-Farha","year":"2015","journal-title":"Sci Rep"},{"key":"key-10.4103\/2230-8210.238127-40","first-page":"7011","volume-title":"Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis","author":"Garc\u00eda-Compe\u00e1n","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-41","first-page":"341","volume-title":"Diabetes mellitus at the time of diagnosis of cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis, but not with increased mortality","author":"Wlazlo","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"key-10.4103\/2230-8210.238127-42","first-page":"1490","volume-title":"Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis","author":"Sigal","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-43","first-page":"198","volume-title":"Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma","author":"Huo","year":"2010","journal-title":"Liver Int"},{"key":"key-10.4103\/2230-8210.238127-44","first-page":"823","volume-title":"Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C","author":"Elkrief","year":"2014","journal-title":"Hepatology"},{"key":"key-10.4103\/2230-8210.238127-45","first-page":"833","volume-title":"Metabolic syndrome after liver transplantation: Shortterm prevalence and pre- and post-operative risk factors","author":"Lunati","year":"2013","journal-title":"Dig Liver Dis"},{"key":"key-10.4103\/2230-8210.238127-46","first-page":"1573","volume-title":"Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis","author":"Yang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-47","first-page":"545","volume-title":"Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection","author":"Sumie","year":"2007","journal-title":"Oncol Rep"},{"key":"key-10.4103\/2230-8210.238127-48","first-page":"2449","volume-title":"Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort","author":"Schlesinger","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/2230-8210.238127-49","first-page":"1","volume-title":"Managing diabetes and liver disease association, guidelines (consensus) development","author":"Hamed","year":"2015","journal-title":"J Endocrinol Diabetes Obes"},{"key":"key-10.4103\/2230-8210.238127-50","first-page":"261","volume-title":"Fructosamine and glycated hemoglobin as indices of glycemic control in patients with liver cirrhosis","author":"Trenti","year":"1990","journal-title":"Ric Clin Lab"},{"key":"key-10.4103\/2230-8210.238127-51","first-page":"2451\u201354","volume-title":"Liver transplantation improves cirrhosis-associated impaired oral glucose tolerance","author":"Shetty","year":"2000","journal-title":"Transplantation"},{"key":"key-10.4103\/2230-8210.238127-52","first-page":"12","volume-title":"Clinical pharmacokinetics of metformin","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/2230-8210.238127-53","first-page":"2601","volume-title":"Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients","author":"Nkontchou","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.238127-54","first-page":"2594","volume-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: Systematic review and meta-analysis","author":"Salpeter","year":"2003","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/2230-8210.238127-55","first-page":"2008\u201316","volume-title":"Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes","author":"Zhang","year":"2014","journal-title":"Hepatol"},{"key":"key-10.4103\/2230-8210.238127-56","first-page":"215","volume-title":"Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs","author":"Balant","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/2230-8210.238127-57","first-page":"456","volume-title":"Mechanisms of the glycaemic effects of sulfonylureas","author":"Ashcroft","year":"1996","journal-title":"Horm Metab Res"},{"key":"key-10.4103\/2230-8210.238127-58","first-page":"873","volume-title":"Hepatotoxicity with thiazolidinediones: Is it a class effect?","author":"Scheen","year":"2001","journal-title":"Drug Saf"},{"key":"key-10.4103\/2230-8210.238127-59","first-page":"229","volume-title":"Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan","author":"Kawamori","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"key-10.4103\/2230-8210.238127-60","first-page":"633","volume-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"key-10.4103\/2230-8210.238127-61","first-page":"1025","volume-title":"Acarbose.An update of its pharmacology and therapeutic use in diabetes mellitus","author":"Balfour","year":"1993","journal-title":"Drugs"},{"key":"key-10.4103\/2230-8210.238127-62","first-page":"184","volume-title":"A randomized controlled trial of acarbose in hepatic encephalopathy","author":"Gentile","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key-10.4103\/2230-8210.238127-63","first-page":"777","volume-title":"Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose","author":"Kihara","year":"1997","journal-title":"J Gastroenterol"},{"key":"key-10.4103\/2230-8210.238127-64","first-page":"151","volume-title":"Hepatotoxicity associated with acarbose therapy","author":"Hsiao","year":"2006","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2230-8210.238127-65","first-page":"484","volume-title":"Hepatic necrosis with cholestasis induced by long-term voglibose administration","author":"Kawakami","year":"2001","journal-title":"Intern Med"},{"key":"key-10.4103\/2230-8210.238127-66","first-page":"e165","volume-title":"Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin","author":"Migoya","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.238127-67","first-page":"75","volume-title":"Pharmacokinetics of linagliptin in subjects with hepatic impairment","author":"Graefe-Mody","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.238127-68","first-page":"501","volume-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","author":"Golightly","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/2230-8210.238127-69","first-page":"524","volume-title":"Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus","author":"Arase","year":"2011","journal-title":"Hepatol Res"},{"key":"key-10.4103\/2230-8210.238127-70","first-page":"253","volume-title":"Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin","author":"Boulton","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/2230-8210.238127-71","first-page":"495","volume-title":"SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"key-10.4103\/2230-8210.238127-72","first-page":"457","volume-title":"SGLT2 inhibitors: A new emerging therapeutic class in the treatment of type 2 diabetes mellitus","author":"Ghosh","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.238127-73","first-page":"691","volume-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"key-10.4103\/2230-8210.238127-74","doi-asserted-by":"crossref","unstructured":"Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: An open- label, parallel- group, single- dose study. Clin Ther 2011;33:1798-808.","DOI":"10.1016\/j.clinthera.2011.09.011"},{"key":"key-10.4103\/2230-8210.238127-75","first-page":"469","volume-title":"Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment","author":"Holmes","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key-10.4103\/2230-8210.238127-76","first-page":"441\u20132","volume-title":"Frequency and characteristics of diabetes in 300 pre-liver transplant patients","author":"Marselli","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"key-10.4103\/2230-8210.238127-77","first-page":"1030\u201340","volume-title":"Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation","author":"Tietge","year":"2004","journal-title":"Liver Transpl"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:36:33Z","timestamp":1786714593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.IJEM_79_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"alternative-id":["238127"],"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_79_18","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}